A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Faviparivir is a pyrazinecarboxamide-derivative antiviral medication originally from Japan and used to treat influenza. Its usage has since been expanded to treat other viral infections, and it works by preventing viruses from being able to copy their genetic material. This duplication process is essential for the virus’ spread and ability to generate symptoms and adversely affect the health of those afflicted with it. Faviparivir works by impeding RNA-polymerase activity within affected cells.
Treatment of Influenza A and B viruses has been the primary application for Faviparivir to date. While it is also used to treat Ebola virus, Yellow fever, and Nipah virus too, these 3 treatments are still under trial. At this time it is also being evaluated as a potential treatment for COVID-19 (coronavirus) but such a usage still hasn’t been approved in the USA or elsewhere. Among other aspects, it is particularly highly touted for an absorption rate of nearly 98%.
Patients may experience any of the following side effects after taking Faviparivir:
Plus, it is important to know that Favipiravir may cause congenital defects and pregnant women should NOT use Favipiravir at any time during their pregnancy.
Favipiravir is sold under the brand name Avigan, and the US FDA for emergency use as a potential COVID-19 treatment in May of 2020.